Oligonucleotide Synthesis Market worth $32.72 billion by 2031 - Exclusive Report by MarketsandMarkets™

The oligonucleotide synthesis market is projected to grow from USD 14.64B in 2026 to USD 32.72B by 2031, implying a 17.4% CAGR, driven by demand for ASOs/siRNAs in oncology and neurological/cardiovascular diseases. The report highlights strong product mix tailwinds (oligonucleotide-based drugs ~71.5% share in 2025; reagents & consumables ~92.1%) and supportive regulatory developments (FDA/EMA draft guidance and 17+ FDA approvals of oligonucleotide therapeutics). Overall, innovation in enzymatic de novo and continuous-flow production is expected to expand capacity and improve scalability.

Analysis

The most investable read-through is not headline TAM expansion but mix shift: the economic value pools sit in recurring reagents, enzymes, and QC consumables, not in one-off synthesis capacity. That favors platform vendors with installed bases and workflow lock-in, especially TMO and DHR, because even modest share gains in high-throughput oligo workflows can lift consumables pull-through faster than instrument unit growth.

The less obvious second-order effect is margin compression for pure-play/custom synthesis providers as enzymatic and continuous-flow methods lower barriers and standardize production. In a market growing this fast, capacity expands quickly; that usually means pricing becomes the battleground, so smaller names like TWST and MRVI are more exposed to a volume-vs-margin tradeoff than the market may assume. If customers increasingly internalize routine oligo production, outsourced growth could undershoot the TAM.

Near term, this is mostly a sentiment item rather than a hard catalyst. The real checkpoints are 1-2 quarters out: consumables growth, instrument backlog, and whether management teams raise 2026/2027 guidance tied to oligo-related demand. Over 6-18 months, regulatory clarity helps adoption but also commoditizes the field, so the structural winner is the picks-and-shovels stack, not the broadest market proxy.

Contrarian view: the consensus may be overestimating how much of the projected market size translates into incremental profit pools. High growth often attracts fast capacity additions and academic/clinical price pressure, which can leave the addressable market bigger but earnings less linear than models imply. In that scenario, the right trade is quality over TAM beta.

Key Decisions for Investors

• Preferred expression: accumulate TMO and DHR on 3-5% weakness over the next 1-2 weeks; target is 8-12% relative outperformance over 3 months if oligo/tool spending filters into consumables growth. Falsifier: no acceleration in consumables commentary in the next two earnings calls.
• Fade any speculative gap-up in TWST and MRVI into the sector headline; use rallies to trim rather than add. Risk/reward is skewed because TAM growth is visible, but margin durability is not yet proven.
• If you want a cleaner pair, long TMO / short TWST over 1-3 months to isolate recurring consumables exposure versus higher execution risk in smaller synthetic biology names. Stop if TWST shows sustained margin expansion or meaningful order-growth reacceleration.
• Watch AZTA as a secondary beneficiary only if customers start expanding storage/sample-management spend alongside oligo throughput. Until then, treat it as a late-cycle laggard rather than a primary long.
• No standalone options trade until we get hard company commentary; the report itself is too diffuse for convexity. Use it as an alert for next quarter guidance revisions rather than a catalyst event.